Haw Par Corporation Limited (HAWPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Haw Par Corporation Limited (HAWPF) trades at $12.00 with AI Score 49/100 (Grade C). Haw Par Corporation Limited is a diversified Singaporean conglomerate with core operations in healthcare, primarily through its globally recognized Tiger Balm and Kwan Loong brands. Market cap: $2.66B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for HAWPF: HAWPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HAWPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HAWPF: the 1 perspectives are evenly split.
How is this calculated? →Haw Par Corporation Limited (HAWPF) Healthcare & Pipeline Overview
Haw Par Corporation Limited, a Singapore-based conglomerate established in 1969, operates across healthcare, investments, and property. It manufactures and distributes topical analgesics like Tiger Balm, manages a portfolio of quoted securities, and owns commercial and industrial real estate. The company also provides leisure alternatives through oceanariums, demonstrating a diversified business model.
What Is the Investment Thesis for HAWPF?
Haw Par Corporation Limited presents a unique investment profile characterized by its diversified business model, strong brand equity in healthcare, and robust financial metrics. The company's Healthcare segment, spearheaded by the iconic Tiger Balm and Kwan Loong brands, provides a stable revenue base with a global reach, contributing to its impressive 56.0% gross margin. This segment's consistent demand for topical analgesics offers resilience against economic fluctuations. The Investments segment, focused on quoted securities, provides exposure to capital market growth, while the substantial real estate portfolio (45,324 sqm in Singapore and Malaysia) generates consistent rental income, enhancing asset stability. With a market capitalization of $2.66B, a P/E ratio of 13.4, and a high profit margin of 115.4%, the company demonstrates efficient operations and strong profitability. The dividend yield of 2.47% further underscores its potential for shareholder returns. Its low Beta of 0.18 suggests lower volatility compared to the broader market. Key growth catalysts include potential geographic expansion for its healthcare products, strategic re-allocation within its investment portfolio, and optimization or expansion of its real estate holdings. Risks include market volatility affecting its investment portfolio and competitive pressures in the healthcare sector.
Based on FMP financials and quantitative analysis
HAWPF Key Highlights
- Market Capitalization of $2.66B reflects the company's significant presence across healthcare, investments, and property sectors.
- A P/E ratio of 13.4 indicates a valuation that may be considered attractive relative to its earnings power within its diversified business model.
- Exceptional Profit Margin of 115.4% demonstrates highly efficient operations and strong profitability across its various segments, particularly from its investment activities.
- Gross Margin of 56.0% highlights the strong pricing power and cost management within its core healthcare manufacturing business.
- A Dividend Yield of 2.47% suggests a commitment to returning value to shareholders, supported by its stable and diversified income streams.
Who Are HAWPF's Competitors?
HAWPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
| LYPHF Luye Pharma Group Ltd. | $0.20 | +0.00% | $815.28M | 49 |
| HAWPY Haw Par Corporation Limited | $54.44 | +1.76% | $3.01B | 50 |
| CHJTF CSPC Pharmaceutical Group Limited | $0.98 | +0.00% | $11.18B | 50 |
| BMYMP Bristol-Myers Squibb Company PFD CONV 2 | $400.00 | -57.46% | $814.59B | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HAWPF's Key Strengths?
- Globally recognized and trusted healthcare brands (Tiger Balm, Kwan Loong) with strong market presence.
- Highly diversified business model across healthcare, investments, property, and leisure, mitigating sector-specific risks.
- Robust financial performance indicated by a 115.4% profit margin and 56.0% gross margin.
- Stable income generation from a substantial portfolio of investment properties.
- Low Beta of 0.18 suggests lower stock price volatility compared to the broader market.
What Are HAWPF's Weaknesses?
- Reliance on traditional topical analgesic products in the healthcare segment, potentially limiting innovation scope.
- Performance of the Investments segment is subject to capital market volatility.
- Leisure segment (oceanariums) can be sensitive to tourism trends and economic downturns.
- Lack of specific details on the strategic direction or future plans for each diversified segment in provided data.
- Limited public information on the specific breakdown of revenue and profit contributions from each segment.
What Could Drive HAWPF Stock Higher?
- Potential expansion of Tiger Balm and Kwan Loong distribution into new international markets, leveraging existing brand recognition to capture additional market share.
- Strategic re-allocation and growth within the Investments segment, capitalizing on favorable market conditions to enhance portfolio returns and overall profitability.
- Optimization of the existing 45,324 square meters of commercial and industrial investment properties through lease renewals, rental adjustments, or strategic renovations to increase recurring income.
- Recovery and growth in the global tourism sector, particularly in Asia, which could boost visitor numbers and revenue for its leisure segment oceanariums.
- Continued strong demand for topical analgesic products, driven by an aging global population and increasing preference for accessible pain relief solutions.
What Are the Key Risks for HAWPF?
- Market volatility in global financial markets could negatively impact the value and returns of Haw Par's significant investment portfolio.
- Intense competition within the topical analgesic market, potentially leading to pricing pressures or reduced market share for Tiger Balm and Kwan Loong.
- Economic downturns or changes in consumer spending habits could adversely affect the performance of its leisure segment and rental income from investment properties.
- The 'Unknown' disclosure status on the OTC market poses a risk due to limited access to comprehensive financial information, hindering investor analysis and potentially impacting liquidity.
- Fluctuations in real estate markets in Singapore and Malaysia could affect the valuation and rental income generated from its investment property portfolio.
What Are the Growth Opportunities for HAWPF?
- **Geographic Expansion and Market Penetration for Healthcare Products:** Haw Par Corporation has a strong foundation with its Tiger Balm and Kwan Loong brands across Singapore, ASEAN, and other Asian countries. A significant growth opportunity lies in deepening market penetration within existing international markets and strategically entering new emerging economies, particularly in regions with growing middle classes and increasing demand for accessible healthcare solutions. This could involve targeted marketing campaigns, establishing new distribution channels, or forming strategic partnerships. The global market for topical pain relief is substantial and continuously expanding, offering ample room for Haw Par to capture additional market share through focused expansion efforts over the next 3-5 years.
- **Strategic Growth of the Investment Portfolio:** The company's Investments segment, which primarily invests in quoted securities, offers a dynamic avenue for growth. By actively managing and strategically re-allocating its capital within this portfolio, Haw Par can capitalize on evolving market trends, sector-specific opportunities, and global economic shifts. This involves sophisticated financial analysis and timely investment decisions to maximize returns. The potential for capital appreciation and increased dividend income from these investments can significantly enhance overall profitability, acting as a flexible growth driver that can adapt to market conditions over a continuous timeline.
- **Optimization and Expansion of Real Estate Holdings:** Haw Par owns and leases 45,324 square meters of commercial and industrial space in Singapore and Malaysia. Opportunities exist to optimize the yield from these existing properties through strategic renovations, tenant mix adjustments, or rental rate reviews. Furthermore, the company could pursue selective acquisitions of new investment properties in high-growth urban centers or industrial hubs to expand its real estate footprint. This segment provides stable, recurring income and potential for capital appreciation, contributing to long-term asset growth. This strategy could unfold over a 5-10 year horizon, depending on market conditions and acquisition opportunities.
- **Diversification and Enhancement of Leisure Offerings:** The leisure segment, currently centered on oceanariums, presents an opportunity for growth through diversification and enhancement of existing attractions. This could involve introducing new interactive exhibits, expanding educational programs, or exploring complementary leisure activities that align with its current offerings. As global tourism recovers and grows, particularly in Asia, there is potential to attract a larger visitor base and increase revenue per visitor. Strategic investments in this segment, potentially over the next 3-7 years, could enhance its contribution to the overall business, leveraging its existing infrastructure and brand presence in the entertainment sector.
- **Brand Extension and Product Innovation in Healthcare:** Leveraging the strong brand equity of Tiger Balm, Haw Par Corporation can explore opportunities for brand extension into new, related healthcare product categories. This could include developing new topical formulations, expanding into adjacent wellness products, or even exploring dietary supplements that align with its traditional health focus. Innovation in packaging, delivery mechanisms, or ingredient formulations could also attract new consumer segments. This strategic move would allow the company to capitalize on its established consumer trust and distribution networks, potentially unlocking new revenue streams within the healthcare market over a 2-5 year timeframe.
What Opportunities Does HAWPF Have?
- Expansion into new geographic markets for healthcare products, particularly emerging economies.
- Strategic acquisitions or development within the investment property portfolio to enhance asset value and rental income.
- Leveraging existing brand equity to introduce new healthcare or wellness products.
- Growth in the leisure and tourism sector, particularly in Asia, boosting oceanarium visitor numbers.
- Optimizing the investment portfolio to capitalize on specific sector trends or market conditions.
What Threats Does HAWPF Face?
- Intense competition in the topical analgesic market from both established brands and new entrants.
- Economic downturns impacting consumer spending on leisure and real estate markets.
- Regulatory changes in the pharmaceutical or healthcare industries affecting product distribution or formulation.
- Volatility in global financial markets impacting the value and returns of the investment portfolio.
- Currency fluctuations affecting international sales and investment values.
What Are HAWPF's Competitive Advantages?
- Strong, globally recognized brand equity for Tiger Balm and Kwan Loong, built over decades, fostering consumer trust and loyalty.
- Diversified revenue streams from healthcare, investments, real estate, and leisure, reducing reliance on any single market or industry.
- Established distribution networks for healthcare products across multiple international markets.
- Significant asset base in investment properties providing stable, recurring rental income.
- Prudent management of a substantial investment portfolio, contributing to robust financial performance.
What Does HAWPF Do?
Haw Par Corporation Limited, incorporated in 1969 and headquartered in Singapore, has evolved into a diversified conglomerate with significant operations across several key segments: Healthcare, Investments, and Others. The company's foundational and most widely recognized business lies within its Healthcare segment, where it manufactures, markets, and distributes topical analgesic products. This segment is anchored by the globally renowned Tiger Balm and Kwan Loong brands, which have established a strong presence not only in Singapore and ASEAN countries but also across other Asian markets and internationally. These brands are synonymous with traditional pain relief and have built decades of consumer trust, contributing a stable and recurring revenue stream to the corporation. Beyond its healthcare stronghold, Haw Par Corporation operates a substantial Investments segment. This segment primarily focuses on strategic investments in quoted securities, allowing the company to leverage capital markets for growth and diversification. The prudent management of this portfolio contributes significantly to the company's overall profitability, as evidenced by its high profit margin. Furthermore, the 'Others' segment encompasses a diverse range of activities, including real estate and leisure. Haw Par owns and leases a portfolio of investment properties, comprising commercial and industrial spaces across Singapore and Malaysia, totaling a lettable area of 45,324 square meters. These properties generate rental income, providing another stable asset base and revenue stream. Additionally, the company offers family and tourist-oriented leisure alternatives, principally through its ownership and operation of oceanariums. This unique blend of healthcare manufacturing, financial investments, real estate holdings, and leisure operations positions Haw Par Corporation Limited as a multifaceted entity with a broad economic footprint and a resilient business model designed to navigate varied market conditions.
What Products and Services Does HAWPF Offer?
- Manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands globally.
- Invests in a portfolio of quoted securities, managing these assets for capital appreciation and income.
- Owns and leases commercial and industrial investment properties in Singapore and Malaysia.
- Provides family and tourist-oriented leisure alternatives, primarily through oceanariums.
- Offers management support services to its subsidiaries and potentially third parties.
- Leases land, building, and office space as part of its property management activities.
How Does HAWPF Make Money?
- Generates revenue from the sale of healthcare products (Tiger Balm, Kwan Loong) through global distribution networks.
- Earns investment income and capital gains from its portfolio of quoted securities.
- Receives rental income from its commercial and industrial investment properties.
- Derives income from admissions and related services at its leisure attractions (oceanariums).
- Provides management support services and earns fees for leasing land, building, and office space.
What Industry Does HAWPF Operate In?
Haw Par Corporation Limited operates within the broader healthcare sector, specifically in the 'Drug Manufacturers - General' industry, yet its business model significantly diversifies beyond this core. The topical analgesic market, where its Tiger Balm and Kwan Loong brands compete, is characterized by established consumer preferences and a mix of traditional remedies and modern pharmaceutical products. This segment benefits from consistent demand for pain relief solutions, particularly in aging populations and regions with high physical labor. Haw Par's strong brand recognition provides a competitive edge in this mature market. Beyond healthcare, the company's substantial investment and property portfolios position it uniquely, allowing it to capitalize on capital market trends and real estate cycles in Singapore and Malaysia. This diversification insulates it from sole reliance on the healthcare industry's specific dynamics, such as regulatory changes or intense R&D requirements typical of novel drug development. Its leisure segment, though smaller, taps into the tourism and entertainment industry, further broadening its market exposure.
Who Are HAWPF's Key Customers?
- Consumers seeking topical pain relief products globally, including individuals and households.
- Institutional and retail investors who are indirect beneficiaries of the company's investment activities.
- Commercial tenants and industrial businesses leasing space in Singapore and Malaysia.
- Tourists and local families visiting its oceanariums and leisure facilities.
- Subsidiaries and potentially external entities utilizing its management support services.
HAWPF Valuation & Market Position
With a $2.66B market cap, Haw Par Corporation Limited sits in the mid-cap segment of the market. Relative to its peer group, HAWPF's quantitative score of 49/100 is below the peer average of 60/100.
ROE 6%Key Financial Metrics
Return on equity for Haw Par Corporation Limited stands at 6.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.0%, showing how much profit it generates from its asset base. HAWPF trades at a trailing price-to-earnings ratio of 13.37, below the Healthcare sector average of ~23x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Haw Par Corporation Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 17.14 places it in the safe zone, indicating low near-term bankruptcy risk.
HAWPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Globally recognized and trusted healthcare brands (Tiger Balm, Kwan Loong) with strong market presence.
- Highly diversified business model across healthcare, investments, property, and leisure, mitigating sector-specific risks.
- Robust financial performance indicated by a 115.4% profit margin and 56.0% gross margin.
- Stable income generation from a substantial portfolio of investment properties.
Bear Case
- Reliance on traditional topical analgesic products in the healthcare segment, potentially limiting innovation scope.
- Performance of the Investments segment is subject to capital market volatility.
- Leisure segment (oceanariums) can be sensitive to tourism trends and economic downturns.
- Lack of specific details on the strategic direction or future plans for each diversified segment in provided data.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HAWPF Latest News
No recent news available for HAWPF.
HAWPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HAWPF.
Price Targets
Wall Street price target analysis for HAWPF.
HAWPF MoonshotScore
What does this score mean?
The MoonshotScore rates HAWPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ee Lim Wee
Managing Director
The specific career history, educational background, previous roles, and credentials for Ee Lim Wee are not provided in the available source data. However, as the Managing Director, Ee Lim Wee is responsible for overseeing the strategic direction and operational management of Haw Par Corporation Limited, which encompasses its diverse business segments including healthcare, investments, property, and leisure. The role involves managing a significant workforce of 595 employees across its various operations.
Track Record: Specific key achievements, strategic decisions, or company milestones directly attributable to Ee Lim Wee's leadership are not detailed in the provided information. As Managing Director, Ee Lim Wee is presumed to be instrumental in guiding the company's multi-faceted operations and maintaining its strong financial performance, including its high profit and gross margins, and its consistent dividend yield. The company's continued operation and diversification since its incorporation in 1969 suggest a stable and experienced leadership.
HAWPF OTC Market Information
Haw Par Corporation Limited trades on the OTC market under the 'OTC Other' tier. This tier represents companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Companies in this tier typically have limited public disclosure, which can make it challenging for investors to access comprehensive and timely financial data. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards and regulatory oversight, 'OTC Other' companies operate with significantly less transparency and regulatory scrutiny, impacting investor confidence and accessibility to information.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Disclosure: The 'Unknown' disclosure status means investors may not have access to current and comprehensive financial reports, making informed decision-making challenging.
- Lower Liquidity: Trading on the 'OTC Other' tier typically results in lower trading volumes and wider bid-ask spreads, making it difficult to execute trades efficiently.
- Price Volatility: Reduced transparency and liquidity can lead to greater price fluctuations and potentially less stable stock performance.
- Lack of Regulatory Oversight: OTC Other companies are subject to less stringent reporting requirements and regulatory scrutiny compared to major exchanges, increasing investment risk.
- Difficulty in Valuation: The absence of consistent and reliable financial data makes it harder for investors to accurately value the company and assess its intrinsic worth.
- Verify the company's official website for any available financial statements or annual reports not found on OTC Markets.
- Research any news articles or press releases from reputable financial news sources specific to Haw Par Corporation Limited.
- Examine the company's business operations and market position in Singapore and ASEAN countries through independent research.
- Assess the stability and profitability of its core healthcare brands (Tiger Balm, Kwan Loong) through industry reports.
- Investigate the value and performance of its investment properties and quoted securities portfolio through external market data.
- Understand the regulatory environment for its healthcare and leisure operations in its primary markets.
- Evaluate the management team's experience and track record, if information becomes available through other channels.
- Long operating history since 1969, indicating established business operations and resilience.
- Globally recognized brands like Tiger Balm and Kwan Loong, suggesting a legitimate and successful product line.
- Tangible assets including investment properties (45,324 sqm) and a portfolio of quoted securities.
- Headquartered in Singapore, a well-regulated financial hub, which may imply a certain level of corporate governance.
- A significant employee base of 595, indicating a substantial and active enterprise.
HAWPF Healthcare Stock FAQ
What does Haw Par Corporation Limited do?
Haw Par Corporation Limited is a diversified conglomerate based in Singapore, operating across four primary segments. Its core business is in healthcare, where it manufactures, markets, and distributes globally recognized topical analgesic products under the Tiger Balm and Kwan Loong brands. Beyond healthcare, the company manages a substantial Investments segment, primarily focused on quoted securities, which contributes significantly to its financial performance. Additionally, Haw Par owns and leases a portfolio of commercial and industrial investment properties totaling 45,324 square meters in Singapore and Malaysia, generating rental income. The company also operates a leisure segment, providing family and tourist-oriented attractions, notably oceanariums. This multi-faceted approach allows Haw Par to generate revenue from diverse sources.
What are the key growth opportunities for HAWPF in healthcare?
For Haw Par Corporation Limited, key growth opportunities in the healthcare sector primarily revolve around leveraging its established brands, Tiger Balm and Kwan Loong. One significant avenue is geographic expansion, deepening market penetration in existing international markets and strategically entering new emerging economies where demand for accessible pain relief products is growing. This could involve targeted marketing, new distribution partnerships, or localized product adaptations. Another opportunity lies in brand extension, where the company could explore introducing new, related healthcare or wellness products under its trusted brand names, capitalizing on consumer loyalty. Innovation in product formulations or delivery methods could also attract new consumer segments, ensuring the continued relevance and growth of its core healthcare offerings.
How does Haw Par Corporation Limited manage its diverse portfolio of healthcare, investments, and leisure?
Haw Par Corporation Limited manages its diverse portfolio through a segmented operational structure, allowing each business unit to focus on its specific market dynamics while benefiting from the corporate umbrella. The Healthcare segment operates with established manufacturing and global distribution networks for its Tiger Balm and Kwan Loong brands. The Investments segment is actively managed to optimize returns from quoted securities, adapting to market conditions. The property segment focuses on asset management, leasing, and potentially development of its commercial and industrial spaces. The leisure segment manages its oceanariums to attract visitors and generate revenue. This diversified approach helps mitigate risks associated with any single industry, providing multiple revenue streams and contributing to the company's overall financial stability and high profit margins.
What are the main risks for HAWPF?
Haw Par Corporation Limited faces several key risks inherent to its diversified operations. In the healthcare segment, intense competition from both established pharmaceutical companies and emerging brands poses a continuous threat to market share and pricing power for its Tiger Balm and Kwan Loong products. The Investments segment is exposed to the inherent volatility of global financial markets, which can impact the value and returns of its quoted securities portfolio. Its real estate holdings are subject to fluctuations in property markets in Singapore and Malaysia, affecting rental income and asset valuations. Furthermore, the leisure segment is sensitive to economic downturns, changes in tourism trends, and public health crises. As an OTC-traded stock with 'Unknown' disclosure status, investors also face risks related to limited transparency and potentially lower liquidity.
How does trading on the OTC market impact HAWPF investors?
Trading on the OTC market, specifically in the 'OTC Other' tier, significantly impacts HAWPF investors by introducing several challenges. The 'Unknown' disclosure status means that comprehensive and timely financial information may not be readily available, making it difficult for investors to conduct thorough due diligence and make informed decisions. This lack of transparency can lead to greater uncertainty regarding the company's financial health and operational performance. Furthermore, OTC Other stocks typically experience lower trading volumes and wider bid-ask spreads compared to exchange-listed securities, resulting in reduced liquidity. This can make it harder for investors to buy or sell shares quickly at desired prices, potentially leading to greater price volatility and increased transaction costs. Investors in HAWPF must be prepared for these inherent characteristics of the OTC market.
What are the key factors to evaluate for HAWPF?
Haw Par Corporation Limited (HAWPF) holds an AI score of 49/100 (low). P/E: 13.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does HAWPF data refresh on this page?
HAWPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HAWPF's recent stock price performance?
Haw Par Corporation Limited (HAWPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Globally recognized and trusted healthcare brands (Tiger Balm, Kwan Loong) with strong market presence. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Specific details for CEO background and track record were not provided in the source data, leading to 'Unknown' entries.
- FMP PEER TICKERS were not provided, so competitors are listed as 'Unknown'.
- Detailed revenue breakdown by segment was not provided, limiting specific analysis of segment contributions to overall profitability.
- Specific market sizes and timelines for growth opportunities are inferred based on general industry knowledge and company context, as exact figures were not provided in the source.